Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced...
BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer...
Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924...
Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicitiesTrial...
BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer...
Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia)New non-clinical data demonstrate...
On track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC) in...
Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple toxicities to all patients with p53-mutated...
BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to develop medicines to...
Plans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22Planned readouts for ongoing...